Recent News

• 12.09.2025 - Gelteq Signs Three Year Sales Agreement with Shenzhen Mana Health Management Co. Strengthening Gelteq’s Nutritional Product Expansion into China
• 12.05.2025 - Gelteq Preclinical Study Demonstrates Enhanced Oral Delivery of Oil-Soluble and Poorly Soluble Drugs Using Its Gel-Based Platform
• 12.02.2025 - Gelteq to Present at Investor Summit Virtual on December 9, 2025
• 11.24.2025 - Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
• 10.23.2025 - Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
• 10.09.2025 - Gelteq Announces New Product Development Agreement with Melbourne Health for Novel Bowel Polyp Growth Reduction Compound
• 09.12.2025 - Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner
• 09.05.2025 - Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

Recent Filings

• 12.09.2025 - EX-99.1 EX-99.1
• 12.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.17.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 11.03.2025 - NT 20-F Notification of inability to timely file Form 20-F
• 08.29.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 08.29.2025 - EFFECT Notice of Effectiveness
• 08.28.2025 - CORRESP Correspondence
• 07.25.2025 - F-1/A Registration statement for certain foreign private issuers
• 07.08.2025 - UPLOAD SEC-generated letter
• 07.01.2025 - F-1 Registration statement for certain foreign private issuers